Connexin 32 potentiates vinblastine-induced cytotoxicity in renal cell carcinoma cells

Molecular Carcinogenesis

Volumn 46, Issue 3, 2007, Pages 215-224

  Sato, Hiromi ^a,b   Senba, Hironobu ^a   Virgona, Nantiga ^a   Fukumoto, Keiko ^a   Ishida, Tatsuya ^a   Hagiwara, Hiromi ^a,c   Negishi, Etsuko ^b   Ueno, Koichi ^b   Yamasaki, Hiroshi ^d   Yano, Tomohiro ^a  

^a NATIONAL INSTITUTE OF HEALTH AND NUTRITION   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c The Human Health Sciences Foundation   (Japan)

^d KWANSEI GAKUIN UNIVERSITY   (Japan)

Author keywords

Connexin 32; Renal cell carcinoma; Vinblastine

Indexed keywords

ANTINEOPLASTIC AGENT; CONNEXIN 32; GAP JUNCTION PROTEIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; SMALL INTERFERING RNA; VINBLASTINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CARCINOMA CELL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; SOLID TUMOR; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA, RENAL CELL; CELL CYCLE; CELL PROLIFERATION; COMBINED MODALITY THERAPY; CONNEXINS; CYTOCHROMES C; DRUG RESISTANCE, MULTIPLE; HUMANS; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOCHONDRIA; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED; VINBLASTINE;

EID: 33947155835     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20267     Document Type: Article

References (45)

1. Landis SH, Murray T, Bolden S, Eino PA. Cancer statistics 1999. CA Cancer J Clin 1999;49:8-31.
2. Hrunshesky WJ, Murphy GP. Current status of the therapy of advanced renal carcinoma. J Surg Oncol 1977;9:277-288.
3. Torti FM. Treatment of metastatic renal cell carcinoma. Recent results. Cancer Res 1983;85:123-142.
4. Harris DT. Hormonal therapy and chemotherapy of renal cell carcinoma. Semin Oncol 1987;10:422-430.
5. Motzer RJ, Russo P. Systemic therapy for renal cell carcinoma. J Urol 2000;163:408-417.
6. Yagoda A, Abi-Rached B, Petryla D. Chemotherapy for advanced renal cell carcinoma, 1983-1993. Semin Oncol 1995;22:42-60.
7. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alpha-2a, or both in metastatic renal-cell carcinoma. New Engl J Med 1998;338:1272-1278.
8. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999;39:361-398.
9. Naito S, Sakamoto N, Kotoh S, Goto K, Matsumoto T, Kumazawa J. Expression of P-glycoprotein and multidrug resistance in renal cell carcinoma. Eur Urol 1993;24: 156-160.
10. Ford JM, Hait WN. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 1990;42: 155-199.
11. Yonezawa Y, Nagashima Y, Sato H, et al. Contribution of the Src family of kinases to the appearance of malignant phenotypes in renal cancer cells. Mol Carcinogenesis 2005;43:188-197.
12. 2-terminal kinase activation contributes to hypoxia-inducible factor 1α-dependent P-glycoprotein expression in hypoxia. Cancer Res 2004;64:9057-9061.
13. Gary MJ, Zhang J, Ellis LM, et al. HIF-1α, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005;24:3110-3120.
14. Mesnil M, Yamasaki H. Cell-cell communication and growth control of normal and cancers: Evidence and hypothesis. Mol Carcinogenesis 1993;7:14-17.
15. Mesnil M. Connexins and cancer. Biol Cell 2002;94: 493-500.
16. Duflot-Dancer A, Mesnil M, Yamasaki H. Dominant-negative abrogation of connexin-mediated cell growth control by mutant connexin genes. Oncogene 1997;15:2151-2158.
17. Fujimoto E, Sato H, Shirai S, et al. Connexin 32 as a tumor suppressor gene in a metastatic renal cell carcinoma cell line. Oncogene 2005;24:3684-3690.
18. Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: Role of gap-junctional intercellular communication. Cancer Res 2000;60:3989-3999.
19. Blajeski AL, Kottke TJ, Kaufmann SH. A multistep model for paclitaxel-induced apoptosis in human breast cancer cell lines. Exp Cell Res 2001;270:277-288.
20. Cliby WA, Lewis KA, Lilly KK, Kaufmann SH. S phase and G2 arrests induced by topoisomerase I poisons are dependent on ATR kinase function. J Biol Chem 2002;277:1599-1606.
21. Suliman A, Lam A, Datta R, Srivastava RK. Intracellular mechanisms of TRAIL: Apoptosis through mitochondrial-dependent and -independent pathways. Oncogene 2001; 20:2122-2133.
22. Glaser T, Weller M. Caspase-dependent chemotherapy-induced death of glioma cells requires mitochondria cytochrome c release. Biochem Biophys Res Commun 2001;281: 322-327.
23. Yano T, Zissel G, Muller-Qernheim J, Shin SJ, Satoh H, Ichikawa T. Prostaglandin E2 reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3. FEBS Lett 2002;518:154-158.
24. Yano T, Yamasaki H. Regulation of cellular invasion and matrix metalloproteinase activity in HepG2 cell by connexin 26 transfection. Mol Carcinogenesis 2001;31:101-109.
25. Pines J, Hunter T. Human cylins A and B1 are differentially located in the cell and undergo cell cycle-dependent nuclear transport. J Cell Biol 1991;115:1-17.
26. Hagting A, Jackman M, Simpson K, Pines J. Translocation of cyclin B1 to the nucleus at prophase requires a phosphorylation-dependent nuclear important signal. Curr Biol 1999; 9:680-689.
27. Kamei J, Toyofuku T, Hori M. Negative regulation of p21 by catenin/TCF signaling: A novel mechanism by which cell adhesion molecules regulate cell proliferation. Biochem Biophys Res Commun 2003;312:380-387.
28. King TJ, Gurley KE, Prunty J, Shin JL, Kemp CJ, Lampe PD. Deficiency in the gap junction protein connexin 32 alters p27Kip1 tumor suppression and MAPK activation in a tissue-specific manner. Oncogene 2005;24:1718-1726.
29. Carre M, Andre N, Carles G, et al. Tubulin is an inherent component of mitochondrial membranes that interacts with the voltage-dependent anion channel. J Biol Chem 2002; 277:33664-33669.
30. Zoratti M, Szabo I. The mitochondrial permeability transition. Biochim Biophys Acta 1995;1241:139-176.
31. Srivastava RK, Sollott SJ, Khan L, Hansford R, Lakatta EG, Longo DL. Bcl-2 and Bcl-X(L) block thapsigargin-induced nitric oxide generation, c-Jun NH(2)-terminal kinase activity, and apoptosis. Mol Cell Biol 1999;19:5659-5674.
32. Fujimoto E, Satoh H, Negishi E, et al. Negative growth control of renal cell carcinoma cell by connexin 32: Possible involvement of Her-2. Mol Carcinogenesis 2004; 40:135-142.
33. Nelson RL. The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer. Med Pediatr Oncol 1982; 10:115-127.
34. Liu JH, Yang MH, Fan FS, et al. Tamoxifen and colchicines-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: A phase II study. Urology 2001;57:650-654.
35. Jordan MA, Wilson L. Microtubules and actin filaments: Dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998;10:123-130.
36. Blajeski AL, Phan VA, Kottke TJ, Kaufmann SH. G1 and G2 cell-cycle arrest following microtubule depolymerization in human breast cancer cells. J Clin Invest 2002;110: 91-99.
37. Mollinedo F, Gajate C. Microtubules, microtubule-interfering agents and apoptosis. Apoptosis 2003;8:413-450.
38. Pourroy B, Carre M, Honore S, et al. Low concentrations of vinflunine induce apoptosis in human SK-N-SH neuroblastoma cells through a postmitotic G1 arrest and a mitochondrial pathway. Mol Pharmacol 2004;66:580-591.
39. Andre N, Braguer D, Brasseur G, et al. Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells. Cancer Res 2000;60:5349-5353.
40. Krutovskikh VA, Piccoli C, Yamasaki H. Gap junction intercellular communication propagates cell death in cancerous cells. Oncogene 2002;21:1989-1999.
41. Vinken M, Vanhaecke T, Papeleu P, Snykers S, Henkens T, Rogiers V. Connexins and their channels in cell growth and cell death. Cell Signal 2005;18:592-600.
42. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: A fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-196.
43. Yano T, Ito F, Kobayashi K, et al. Hypermethylation of the CpG island of connexin 32, a candiate tumor suppressor gene in renal cell carcinomas from hemodialysis patients. Cancer Lett 2004;208:137-142.
44. Omori Y, Krutovskikh V, Mironov N, Tsuda H, Yamasaki H. Cx32 gene mutation in a chemically induced rat liver tumor. Carcinogenesis 1996;17:2077-2080.
45. Shirai S, Hagiwara H, Sato H, et al. Prevention of renal cell carcinoma from hemodialysis patients by regulating epigenetic factors. Kidney Int 2005;67:2506-2507.